Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.

    IFS, the leading provider of Industrial AI software, announced at Industrial X Unleashed a strategic partnership with 1X Technologies (1X), to jointly industrialize humanoid robotics for asset-intensive industries. The collaboration will combine 1X’s humanoid robots with IFS.ai to develop and deploy production-ready robotics solutions alongside select customers across manufacturing, utilities, aviation and other industrial settings. The […] The post IFS and 1X Technologies Partner to Bring Industrial AI to the Physical World appeared first on Web-Release.